⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41332 | 0.90 | — | — | |
| SCHEMBL1238744 | 0.84 | MEN1 (0.31) | — | |
| SCHEMBL6213386 | 0.81 | — | — | |
| SCHEMBL5666576 | 0.67 | — | — | |
| SCHEMBL27822849 | 0.62 | — | — | |
| SCHEMBL1869916 | 0.62 | — | — | |
| SCHEMBL27945191 | 0.62 | — | — | |
| SCHEMBL37882 | 0.62 | — | — | |
| SCHEMBL11141919 | 0.60 | — | — | |
| SCHEMBL4498589 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024056678-A1 | NOVEL NOOTROPIC PRODRUGS OF PHENETHYLAMINE | MIHKAL GMBH (CH) | 2024-03-21 | — | — | WO | disclosed |
| CN-113493628-B | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| US-10017603-B2 | One component epoxy curing agents comprising hydroxyalkylamino cycloalkanes | EVONIK DEGUSSA GMBH (DE) | 2018-07-10 | — | — | US | disclosed |
| US-20170342197-A1 | ONE COMPONENT EPOXY CURING AGENTS COMPRISING HYDROXYALKYLAMINO CYCLOALKANES | EVONIK OPERATIONS GMBH (DE) | 2017-11-30 | — | — | US | disclosed |
| EP-2981565-B1 | ONE COMPONENT EPOXY CURING AGENTS COMPRISING HYDROXYALKYLAMINO CYCLOALKANES | EVONIK DEGUSSA GMBH (DE) | 2017-10-04 | — | — | EP | disclosed |
| US-9738750-B2 | One component epoxy curing agents comprising hydroxyalkylamino cycloalkanes | Veonik Degussa GmbH (DE) | 2017-08-22 | — | — | US | disclosed |
| EP-3199564-A1 | ONE COMPONENT EPOXY CURING AGENTS COMPRISING HYDROXYALKYLAMINO CYCLOALKANES | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-2546242-B1 | Cannabinoid receptor ligands | ABBVIE INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2546242-A1 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2457903-A1 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2346843-A2 | SUBSTITUTED BENZAMIDES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100063022-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-11 | — | — | US | disclosed |
| WO-2010028338-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-11 | — | — | WO | disclosed |
| US-7608723-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-1H-benzimidazol-2-yl)-2-methylpropyl]-4-chlorobenzamide;kinesin spindle protein modulators; anticarcinogenic agents; in vivo stability, bio-availability; diagnosis/medical/;antitumor agents hyperplasia; restinosis; antiinflammatory agents; cardiac hypertrophy | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20060084687-A1 | Indole and benzimidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20050069541-A1 | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2005-03-31 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |